Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update

James Samuel McLaren, James S. McLaren, McLaren JS, Morris E, Edward Morris, Janice Rymer, Rymer J
Menopause international · 2012 · vol. 18(2) , pp. 68–72 · doi:10.1258/mi.2012.012008 · PMID:22611225 · W2008686181
Review OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

This review updates evidence on gonadotrophin-releasing hormone analogues combined with add-back therapy for sex hormone-dependent disorders, detailing their efficacy and improved tolerability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Gonadotrophin receptor hormone analogues (GnRHa) have been used in a range of sex hormone-dependent disorders. In the management of premenstrual syndrome, they can completely abolish symptoms. The success of GnRHa in the treatment of endometriosis and adjuvant therapy in the management of fibroids is proven. This efficacy does not come without a cost and the side-effects of the hypo-estrogenic state have limited their application. The use of add-back therapy to counter these effects has enabled wider application, longer durations of treatment and an increase in compliance. This review article is an update on the evidence supporting gonadotrophin receptor hormone analogues in combination with add-back therapy.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Premenstrual Syndrome Bone Density Bone Density Bone Density Bone Density Conservation Agents Bone Density Conservation Agents Bone Density Conservation Agents Calcitonin Calcitonin Calcitonin Diphosphonates Diphosphonates Diphosphonates Endometriosis Endometriosis Endometriosis Estrogen Antagonists Estrogen Antagonists

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (30)

Cited by (8)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:10:20.980095+00:00
License: CC0 · commercial use OK